RxDoctor Payments DataLook up a doctor →

Roberto Leon Ferre, MD

Medical Oncology · Rochester, MNNPI 1427361377

Payments from drug & device makers

$661,271in general payments, 2019–2025

Across 41 payments — averaging $16,129 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$572K
  • Pfizer$40K
  • Gilead$22K
  • Immunomedics, Inc.$17K
  • AstraZeneca$9K
  • Merck$2K

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis8$571,882
Pfizer4$40,000
Gilead17$21,796
Immunomedics, Inc.2$16,690
AstraZeneca9$8,767
Merck1$2,135

How this compares

$661,271 in reported general payments places this provider in the 65th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,432,879
Medicare patients
472
Services billed
91,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →